Whole-Body MRI Is an Effective Imaging Modality for Hematological Malignancy Treatment Response Assessment: A Systematic Review and Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Mar 7

PMID 35251996

Authors

Guisen Lin

Xiaodan Zong

Yaowen Li

Weiting Tan

Weisheng Sun

Siqi Zhang

Yungen Gan

Hongwu Zeng

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate the diagnostic accuracy of whole-body MRI (WB-MRI) for assessment of hematological malignancies' therapeutic response.

Methods: PubMed, Embase, and Web of Science were searched up to August 2021 to identify studies reporting the diagnostic performance of WB-MRI for the assessment of hematological malignancies' treatment response. A bivariate random-effects model was applied for the generation of the pooled diagnostic performance.

Results: Fourteen studies with 457 patients with lymphoma, multiple myeloma, and sarcoma (very small proportion) were analyzed. Overall pooled sensitivity and specificity of WB-MRI were 0.88 (95% CI: 0.73-0.95) and 0.86 (95% CI: 0.73-0.93), respectively. Studies using whole-body diffusion-weighted imaging (WB-DWI) showed higher sensitivity than those that did not (0.94 vs. 0.55, p = 0.02). The pooled concordance rate of WB-MRI to assess hematological malignancies' treatment response with reference standard was 0.78 (95% CI: 0.59-0.96). WB-MRI and PET/CT showed similar diagnostic performance (sensitivity [0.83 vs. 0.92, p = 0.11] and specificity [0.87 vs. 0.76, p = 0.73]).

Conclusion: WB-MRI has high diagnostic performance for hematological malignancies' treatment response assessment. The adding of WB-DWI is strongly associated with increased sensitivity.

Citing Articles

Imaging evaluation of lymphoma in pregnancy with review of clinical assessment and treatment options.

DellAquila K, Hodges H, Moshiri M, Katz D, Elojeimy S, Revzin M Abdom Radiol (NY). 2023; 48(5):1663-1678.

PMID: 36595067 PMC: 9808767. DOI: 10.1007/s00261-022-03779-9.

The Diagnostic Efficiency of Quantitative Diffusion Weighted Imaging in Differentiating Medulloblastoma from Posterior Fossa Tumors: A Systematic Review and Meta-Analysis.

Luo Y, Zhang S, Tan W, Lin G, Zhuang Y, Zeng H Diagnostics (Basel). 2022; 12(11).

PMID: 36428860 PMC: 9689934. DOI: 10.3390/diagnostics12112796.

References

Nievelstein R, Littooij A . Whole-body MRI in paediatric oncology. Radiol Med. 2015; 121(5):442-53. PMC: 4837204. DOI: 10.1007/s11547-015-0600-7. View

Latifoltojar A, Punwani S, Lopes A, Humphries P, Klusmann M, Menezes L . Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including F-FDG-PET-CT. Eur Radiol. 2018; 29(1):202-212. PMC: 6291431. DOI: 10.1007/s00330-018-5445-8. View

Giles S, Messiou C, Collins D, Morgan V, Simpkin C, West S . Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014; 271(3):785-94. DOI: 10.1148/radiol.13131529. View

Lan H, Lin G, Zhong W . A meta-analysis of the added value of diffusion weighted imaging in combination with contrast-enhanced magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma lesser or equal to 2 cm. Oncol Lett. 2020; 20(3):2739-2748. PMC: 7400770. DOI: 10.3892/ol.2020.11805. View

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

Albano D, Stecco A, Micci G, Sconfienza L, Colagrande S, Reginelli A . Whole-body magnetic resonance imaging (WB-MRI) in oncology: an Italian survey. Radiol Med. 2020; 126(2):299-305. DOI: 10.1007/s11547-020-01242-7. View

Reitsma J, Glas A, Rutjes A, Scholten R, Bossuyt P, Zwinderman A . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005; 58(10):982-90. DOI: 10.1016/j.jclinepi.2005.02.022. View

Tunariu N, Blackledge M, Messiou C, Petralia G, Padhani A, Curcean S . What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. Br J Radiol. 2020; 93(1115):20200562. PMC: 8519652. DOI: 10.1259/bjr.20200562. View

Lin C, Itti E, Luciani A, Zegai B, Lin S, Kuhnowski F . Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study. Invest Radiol. 2011; 46(5):341-9. DOI: 10.1097/RLI.0b013e3182087b03. View

10.

Di M, Huntington S, Olszewski A . Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. Oncologist. 2020; 26(2):120-132. PMC: 7873335. DOI: 10.1002/onco.13610. View

11.

Zaucha J, Chauvie S, Zaucha R, Biggii A, Gallamini A . The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treat Rev. 2019; 77:44-56. DOI: 10.1016/j.ctrv.2019.06.002. View

12.

Theruvath A, Siedek F, Muehe A, Garcia-Diaz J, Kirchner J, Martin O . Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. Radiology. 2020; 296(1):143-151. PMC: 7325702. DOI: 10.1148/radiol.2020192508. View

13.

Xu G, Li C, Zhao L, He Z . Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis. Ann Oncol. 2012; 24(1):96-101. DOI: 10.1093/annonc/mds234. View

14.

Basha M, Hamed M, Refaat R, AlAzzazy M, Bessar M, Mohamed E . Diagnostic performance of F-FDG PET/CT and whole-body MRI before and early after treatment of multiple myeloma: a prospective comparative study. Jpn J Radiol. 2018; 36(6):382-393. DOI: 10.1007/s11604-018-0738-z. View

15.

Zugni F, Padhani A, Koh D, Summers P, Bellomi M, Petralia G . Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. Cancer Imaging. 2020; 20(1):34. PMC: 7216394. DOI: 10.1186/s40644-020-00315-0. View

16.

Hagtvedt T, Seierstad T, Lund K, Londalen A, Bogsrud T, Smith H . Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma. Acta Radiol. 2014; 56(2):152-8. DOI: 10.1177/0284185114526087. View

17.

Paternain A, Garcia-Velloso M, Rosales J, Ezponda A, Soriano I, Elorz M . The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with F-FDG PET-CT. Eur J Radiol. 2020; 133:109403. DOI: 10.1016/j.ejrad.2020.109403. View

18.

Wu X, Kellokumpu-Lehtinen P, Pertovaara H, Korkola P, Soimakallio S, Eskola H . Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography. NMR Biomed. 2011; 24(10):1181-90. DOI: 10.1002/nbm.1689. View

19.

Punwani S, Cheung K, Skipper N, Bell N, Bainbridge A, Taylor S . Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease. Pediatr Radiol. 2013; 43(8):941-9. DOI: 10.1007/s00247-012-2616-7. View

20.

Park H, Kim K, Yoon M, Lee M, Chae E, Lee J . Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. Cancer Imaging. 2020; 20(1):14. PMC: 6993415. DOI: 10.1186/s40644-020-0293-6. View